Developing a Vaccine for Lewy Body Dementia
IND enabling CMC/safety/toxicology studies, submission of IND and pilot Phase 1 clinical trial with PV-1950R vaccine for Lewy Body Dementia (LBD)
['FUNDING_U01'] · INSTITUTE FOR MOLECULAR MEDICINE · NIH-11103129
This project is developing a new vaccine called PV-1950R to help people with Lewy Body Dementia.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | INSTITUTE FOR MOLECULAR MEDICINE (nih funded) |
| Locations | 1 site (HUNTINGTON BEACH, UNITED STATES) |
| Trial ID | NIH-11103129 on ClinicalTrials.gov |
What this research studies
Lewy Body Dementia (LBD) is a severe form of dementia affecting many people, and currently, there are no approved treatments. This project focuses on creating a vaccine, PV-1950R, designed to target a specific protein called alpha-synuclein (αSyn) that builds up in the brains of individuals with LBD. The goal is to prevent or slow down the accumulation of this protein, which is believed to cause the disease's progression. This work involves preparing the vaccine for human use and conducting a small initial clinical trial to test its safety.
Who could benefit from this research
Good fit: Patients diagnosed with Lewy Body Dementia, or potentially those with early signs like rapid eye movement sleep behavior disorder, may be ideal candidates for future participation.
Not a fit: Individuals without Lewy Body Dementia or related conditions would not receive direct benefit from this specific vaccine.
Why it matters
Potential benefit: If successful, this vaccine could offer the first approved treatment for Lewy Body Dementia, potentially slowing its progression or preventing its onset.
How similar studies have performed: Immunotherapy is a promising approach being explored for neurodegenerative diseases, though this specific vaccine is in early development.
Where this research is happening
HUNTINGTON BEACH, UNITED STATES
- INSTITUTE FOR MOLECULAR MEDICINE — HUNTINGTON BEACH, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: AGADJANYAN, MICHAEL G — INSTITUTE FOR MOLECULAR MEDICINE
- Study coordinator: AGADJANYAN, MICHAEL G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia, Alzheimer syndrome